Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 + LGX818 in BRAF Mutant Melanoma
NCT01777776Phase 2Terminated
- Sponsor
- Array BioPharma
- Start
- Jul 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of ribociclib in melanoma (4 arms), sponsored by Array BioPharma. Primary endpoints: Incidence of Dose Limiting Toxicities, Progression Free Survival at 23 months and 1 more. Started Jul 2013; status: terminated.
02
Drugs
ribociclib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01777776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777776.